Solid Tumor Focus Day: Friday, September 26
8:50 am Chair’s Opening Remarks
Highlighting the Existing & Novel Technologies for Solid Tumor Targeting to Gain an Understanding of the Current State of Play
9:00 am eTILÒ & eCARÒ Therapies: CRISPR/Cas9 Engineered T-Cells to Treat Solid Tumors
Synopsis
- CRISPRomics discovery platform identified SOCS1 and Regnase-1 as top T-cell targets enhancing functionality
- Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered TIL (eTILÒ) against solid tumors
- Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered CARTs (eCARÒ) against solid tumors
9:30 am ADI-270, An Allogeneic Armored γδ CAR T-Cell Product with Potential to Address the Challenges of Targeting Solid Tumors
Synopsis
- Share ADI-270 design and product characteristics
- Preclinical data supporting potential to overcome challenges in solid tumor targeting
- Discuss how ADI-270 is differentiated compared to conventional αβ CAR-T benchmarks
10:00 am Strategies to Overcome Challenges with Development of Cell Therapy for Solid Tumors
Synopsis
- Advancing innovative strategies to ‘armor’ cell therapies with the goal of enabling them to resist the immuno-suppressive TME
- We are advancing a portfolio of CAR-Ts and TCR-Ts that aim to unlock a range of important targets in cancer. Preclinical and early clinical data are showing the potential of our approach across hard-to-treat solid cancers
- Beyond our work in solid tumors, we are advancing a novel dual-targeting CAR-T that has potential in hematology and immunology, and which uses a rapid manufacturing process to overcome current challenges in the production of cell therapies
10:30 am Morning Networking Break
Navigating the Tumor Microenvironment & Identifying Novel Targets to Increase Success with Tumor Penetration
11:00 am Honing the Tumor Microenvironment of Solid Tumors to Better Understand How to Target it & Improve Efficacy of Cell Therapy Treatment
Synopsis
- Analyzing the differences in solid tumor microenvironment as compared to hematological tumors
- Overcoming the complexity of solid tumor microenvironment
- Identifying how best to penetrate the tumor microenvironment to increase efficacy
11:30 am Exploring New Targets in Solid Tumors to Improve Tumor Specificity & Reduce Off- Target Toxicities
Synopsis
- Assessing the need for new target identification in solid tumors
- Identifying potential new targets such as Claudin 18.2, HER2 and EFGR that can help with increasing tumor specificity
- Understanding how to develop cell therapies for the new targets
12:00 pm Networking Lunch
Going Beyond the Traditional: Utilizing Novel Cell Types, Armoring Technologies & Cell Sources to Guarantee Success with Solid Tumors
1:00 pm Armoring T-Cells Against Oxidative Stress Breaking Through the Solid Tumor Barrier for Adoptive Cell Therapies
Synopsis
- How Reactive Oxygen Species (ROS) impact the immune function of various immune effector cells
- Ex vivo activation of the Nrf2 pathway triggers a strong protection of cytotoxic lymphocytes against oxidative stress
- Perspectives for improving clinical efficacy in solid tumors for NK-, CAR-T cells and TIL therapybased approaches
1:30 pm Pioneering Engineered Macrophages in Oncology & Beyond
Synopsis
- Exploring CAR-M platform for solid tumor immunotherapy
- Reviewing the clinical program overview of Anti-HER2 CAR-M ex vivo cell therapy
- Utilizing direct in vivo CAR reprogramming for oncology and other disease areas
2:00 pm ACTallo: An Engineered T-Cell Therapy Platform for Adoptive Cell Therapies
Synopsis
- Immatics develops TCR-based cancer immunotherapies by combining the discovery of naturally HLA-presented targets with the discovery of the right T-cell receptors
- T-cell receptor (TCR)-based immunotherapies hold a great potential for the treatment of solid tumors by targeting extra- and intracellular tumor-associated antigens
- For our allogeneic ACT platform, we employ CRISPR/Cas technology to introduce 1) targeted killing capacities by expressing a highly functional TCR or CAR, 2) cloaking technology to avoid fast graft rejection, 3) armoring to counteract the suppressive tumor microenvironment
2:30 pm Afternoon Networking Break
Utilizing the Success in Solid Tumors to Learn from Them & Translate Them to Your Development
3:00 pm Synthetic Immune Receptor, A Next Generation CAR-T Platform
Synopsis
- Describing the current challenges facing cell therapy
- Describing the reasons why CAR-T therapies have failed and especially in solid tumors
- Introducing Synthetic Immune Receptor (SIR), a next generation HLA-independent TCR platform and describing the activity of SIR against solid tumors and blood cancers
3:30 pm Programming T-Cells with Synthetic Immunology to Overcome Solid Tumor Barriers
Synopsis
- Achieving efficacy in solid tumor cell therapy requires addressing challenges of insufficient specificity and potency of conventional designs
- ArsenalBio has developed technologies, manufacturing, and regulatory know-how to make T-cell products with large, multi-functional transgenes to address these challenges
- We are advancing a pipeline of therapies for solid tumor indications